Patents by Inventor Michael Rajesh Stephen

Michael Rajesh Stephen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF
    Publication number: 20240051945
    Abstract: The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these pyrimidine compounds, pharmaceutical compositions containing them, and medicinal applications thereof.
    Type: Application
    Filed: October 30, 2021
    Publication date: February 15, 2024
    Inventors: Gurulingappa Hallur, Naveena Madhyastha, Michael Rajesh Stephen, Bruce Roth, Anjali Pandey, Tracy Saxton, Sridharan Rajagopal, M. Naveen Sadhu
  • PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF
    Publication number: 20230416232
    Abstract: The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these pyrimidine compounds, pharmaceutical compositions containing them, and medicinal applications thereof.
    Type: Application
    Filed: October 30, 2021
    Publication date: December 28, 2023
    Inventors: Gurulingappa Hallur, Naveena Madhyastha, Michael Rajesh Stephen, Bruce Roth, Anjali Pandey, Tracy Saxton
  • GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA
    Publication number: 20230103216
    Abstract: Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.
    Type: Application
    Filed: August 11, 2022
    Publication date: March 30, 2023
    Inventors: Alexander E. Arnold, Douglas C. Stafford, James M. Cook, Charles W. Emala, Gloria Forkuo, Rajwana Jahan, Revathi Kodali, Guanguan Li, Michael Rajesh Stephen
  • Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators
    Patent number: 11447495
    Abstract: Substituted benzo[f]imidazo[1,5-?][1,4]diazepines of formula (I?) target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: September 20, 2022
    Assignees: UWM Research Foundation, Inc., The Trustees of Columbia University in the City of New York
    Inventors: Alexander E. Arnold, Douglas C. Stafford, James M. Cook, Charles W. Emala, Gloria Forkuo, Rajwana Jahan, Revathi Kodali, Guanguan Li, Michael Rajesh Stephen
  • GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA
    Publication number: 20210284649
    Abstract: Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.
    Type: Application
    Filed: August 16, 2017
    Publication date: September 16, 2021
    Inventors: Alexander E. Arnold, Douglas C. Stafford, James M. Cook, Charles W. Emala, Gloria Forkuo, Rajwana Jahan, Revathi Kodali, Guanguan Li, Michael Rajesh Stephen
  • GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
    Patent number: 9879020
    Abstract: Novel methods of treating inflammation and airway constriction using GABAergic compounds with reduced benzo-diazepine-like CNS activity are provided. Novel compounds which selectively target alpha-4 and alpha-5 GABAA receptors and methods of using those compounds to treat bronchoconstriction and inflammation are provided herein.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: January 30, 2018
    Assignees: UWM Research Foundation, Inc., The Trustees of Columbia University in the City of New York
    Inventors: Douglas C. Stafford, James M. Cook, Alexander E. Arnold, Charles W. Emala, George Gallos, Michael Rajesh Stephen
  • NOVEL GABAA AGONISTS AND METHODS OF USING TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA
    Publication number: 20150232473
    Abstract: Novel methods of treating inflammation and airway constriction using GABAergic compounds with reduced benzo-diazepine-like CNS activity are provided. Novel compounds which selectively target alpha-4 and alpha-5 GABAA receptors and methods of using those compounds to treat bronchoconstriction and inflammation are provided herein.
    Type: Application
    Filed: September 20, 2013
    Publication date: August 20, 2015
    Inventors: Douglas C. Stafford, James M. Cook, Alexander E. Arnold, Charles W. Emala, George Gallos, Michael Rajesh Stephen